First-line treatment for eradication of Helicobacter pylori: Still an effective therapy
DOI:
https://doi.org/10.51481/amc.v65i1.1130Keywords:
Drug Resistance, Bacterial, Helicobacter pylori, Stomach Neoplasms, Helicobacter Infections, Disease EradicationAbstract
Aim: The main objective of this study is to determine the response to the firstline treatment regimen with triple standard therapy (amoxicillin, clarithromycin, omeprazole), to eradicate Helicobacter pylori in a certain population. The goal is to determine if the proposed regimen in international guidelines services is still a suitable option for patients in a certain region of Costa Rica.
Methods: The study took place in San Francisco de Asís Hospital, Grecia, Alajuela, Costa Rica. All patients with a Helicobacter pylori infection that were given first- line treatment with triple therapy (amoxicillin, clarithromycin and omeprazole) for its eradication for 14 days, in the period between February of 2017 and February of 2019, were included in the study.
Results: A total of 369 cases were identified. The diagnosis was made with biopsy in 96.4% of patients. Response to first-line treatment was achieved in 90.5% corroborated by fecal antigen in 92.1% of all cases.
Conclusions: This study shows that triple therapy with amoxicillin, clarithromycin and omeprazole for 14 days maintains an adequate level of efficacy. However, it must be considered that these results are from a specific area and may not reflect the reality of the entire country.
Downloads
References
Forman D, Newell DG, Fullerton F, Yarnell JW, Stacey AR, Wald N, et al. Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation. BMJ. 1991; 302:1302-1305. DOI: 10.1136/bmj.302.6788.1302
Correa P. Human gastric carcinogenesis: a multistep and multifactorial process—First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res. 1992; 52:6735-6740.
Morera-Brenes B, Sierra R, Barrantes R, Jonasson J, Nord CE. Helicobacter pylori in a costa rican dyspeptic patient population. Eur J Clin Microbiol Infect Dis. 1994; 253-257. DOI: 10.1007/BF01974546
Blanco-Delgado C, Rivera P, Hernández F, Hevia F, Guillén F, Duran S, et al. Prevalencia de Helicobacter pylori en pacientes atendidos en el Hospital San Juan de Dios, San José, Costa Rica. Rev Biomed. 2001; 12:1-4. DOI: 10.32776/revbiomed.v12i1.250
Fock KM, Graham DY, Malfertheiner P. Helicobacter pylori research: historical insights and future directions. Nat Rev Gastroenterol Hepatol. 2013; 10:495-500. DOI: 10.1038/nrgastro.2013.96
Annibale B, Giulio ED, Caruana P, Lahner E, Capurso G, Bordi C, et al. The long-term effects of cure of Helicobacter pylori infection on patients with atrophic body gastritis. Aliment Pharmacol Ther. 2002; 16:1723-1731. Doi:10.1046/j.1365-2036.2002.01336.x
Sierra R, Muñóz N, Sanabria M, Mora Zúñiga F, Quirós E, Brenes F, et al. Helicobater pylori: ¿es posible la erradicación? Rev costarric salud pública. 1999; 8:37-43.
Randel A. H. pylori Infection: ACG Updates Treatment Recommendations. AFP. 2018; 97:135-137.
Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of helicobacter pylori Infection. Am J Gastroenterol. 2017; 112:212-239. DOI: 10.1038/ajg.2016.563
Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, et al. Management of helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017; 66:6-30. DOI: 10.1136/gutjnl-2022-327745
Graham DY, Lee YC, Wu MS. Rational helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol. 2014; 12:177-186.e3; Discussion e12-13. DOI: 10.1016/j.cgh.2013.05.028
Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010; 59:1143-1153. DOI: 10.1136/gut.2009.192757
Molina-Infante J, Corti R, Doweck J, McNicholl AG, Gisbert JP. Avances recientes en el tratamiento de la infección por Helicobacter pylori. Acta Gastroenterol Latinoam. 2017; 47:75-85
Mobley HL. The role of Helicobacter pylori urease in the pathogenesis of gastritis and peptic ulceration. Aliment Pharmacol Ther. 1996; 10:57-64. DOI: 10.1046/j.1365-2036.1996.22164006.x
Chen YI, Fallone CA. A 14-day course of triple therapy is superior to a 10-day course for the eradication of Helicobacter pylori: A Canadian study conducted in a ‘real world' setting. Can J Gastroenterol Hepatol. 2015; 29:e7-10. DOI: 10.1155/2015/659390
Henao Riveros SC, Quiroga A, Martínez Marín JD, Otero Regino W. Primary resistance to Clarithromycin in Helicobacter pylori isolates. Rev Colomb Gastroenterol. 2009; 24:110-114.
Salas-Aguilar R, Páez-Sáenz R, Avendaño-Alvarado G, Ávalos-Giugliarelli A, Barahona-García R, Lang L, et al. Erradicación de Helicobacter pylori mediante triple terapia (amoxicilina, claritromicina y omeprazole), en pacientes del Hospital Rafael Ángel Calderón Guardia. Acta méd. costarric. 2003; 45:57-61. DOI:10.51481/amc.v45i2.98
Muñoz MS, Rossi MLV, Ferrer L, Medeot R, Najum H, López L, et al. Utilidad del antígeno de Helicobacter pylori en heces como método diagnóstico no invasivo. Acta Gastroenterol Latinoam 2019; 49:22-31.
Graham DY, Dore MP. Helicobacter pylori therapy: a paradigm shift. Expert Rev Anti Infect Ther. 2016; 14:577-585. DOI: 10.1080/14787210.2016.1178065
Gisbert JP, McNicholl AG. Optimization strategies aimed to increase the efficacy of H. pylori eradication therapies. Helicobacter. 2017; 22. DOI: 10.1111/hel.12392
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Acta Médica Costarricense
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Los autores que publican en la revista Acta Médica Costarricense pueden distribuir, copiar, remezclar, retocar, leer, descargar, imprimir, buscar y crear a partir de su obra de modo no comercial, indicando los créditos a la revista y sus autores y compartir su obra en las mismas condiciones. Para ello se aplica la licencia Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional(CC BY-NC-SA 4.0)
